Utility of molecular biology in acute leukæmias at diagnosis and for the evaluation of minimal residual disease;Utilité de la bioligie moléculaire dans le diagnostic des leucémies aiguës et l'évaluation de la maladie résiduelle

Revue du Praticien

Volumn 46, Issue 1, 1996, Pages 42-47

  Gabert, Jean ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ARTICLE; GENETICS; HUMAN; LEUKEMIA; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SOUTHERN BLOTTING;

ACUTE DISEASE; BLOTTING, SOUTHERN; HUMANS; LEUKEMIA; MOLECULAR BIOLOGY; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 4243114405     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis. Cell 1991; 64: 337-50.
2. Rabbitts T. Chromosomal translocations in human cancer. Nature 1994; 372: 143-9.
3. Fey MF, Kulozik AE, Hansen HT, Tobler A. The polymerase chain reaction : a new tool for the detection of minimal residual disease in haematological malignancies. Eur J Cancer 1991; 27: 89-94.
4. Bartram CR. Molecular genetic techniques for detection of minimal residual disease in acute lymphoblastic leukemia: possibilities and limitations. Recent Results Cancer Res 1993; 131: 149-55.
5. Mitelman F, Heim S. Quantitative acute leukemia cytogenetics. Genes Chromosom Cancer 1992; 5: 57-66.
6. Maurer J. Janssen JW, Thiel E et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991; 337: 1055-8.
7. Izraeli S, Janssen JW, Haas OA et al. Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: a comparison between cytogenetic and polymerase chain reaction analyses. Leukemia 1993; 7: 671-8.
8. Biondi A, Rambaldi A, Rossi V et al. Detec-tion of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t (4 ; 11) translocation. Blood 1993; 82: 2943-7.
9. Imamura J, Mioshi I, Koeffler HP. p 53 in hematologic malignancies. Blood 1994; 84: 2412-21.
10. Tong JH, Dong S, Geng JP et al. Molecular rearrangements of the MYL gene in acute promyelocytic leukemia (APL, M3) define a break point cluster region as well as some molecular variants. Oncogene 1992; 7: 311-6.
11. Biondi A, Rambaldi A, Pandolfi PP et al. Molecular monitoring of the my[/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80: 492-7.
12. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t (8; 21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 1991; 88: 10431-4.
13. Liu P, Tarle SA, Hajra A et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261: 1041-4.
14. Jonsson OG, Kitchens RL, Baer RJ, Buchanan GR, Smith RG. Rearrangements of the tal-1 locus as clonal markers for T cell acute lymphoblastic leukemia. J Clin Invest 1991; 87: 2029-35.
15. INK4B) display frequent homozygous deletions in primary cells from T- but not from B- cell lineage acute lymphoblastic leukemia. Blood 1994; 84: 4038-44.
16. Yokota S, Hansen HT, Ludwig WD et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lym phoblastic leukemia patients. Blood 1991; 77: 331-9.
17. Miller WJ, Kakizuka A, Frankel SR et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 2694-8.
18. Nucifora G, Larson RA, RowleyJD. Persistence of the t(8; 21) translocation in patients with AML-M2 in long-term remission patients. Blood 1993; 82: 712-5.
19. Breit M, Beishuizen A, Ludwig WD et al. tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia 1993; 7: 2004-11.
20. Sigaux F. Physiologie et pathologie de la recombinaison V(D). J Med Sciences 1994; 10: 995-1005.
21. Brisco MJ, Condon J, Hughes E et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196-200.